US and EU perspectives on the evolving nature of clinical requirements for biosimilars

The regulatory landscape for biosimilars is undergoing significant change on both sides of the Atlantic. Recent developments signal a potential shift away from the requirement for a clinical efficacy study as an approval requirement in all cases….
By: Hogan Lovells